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SUMMARY – The aim of the study was to assess the role of behavioral factors in persistence of 
human papillomavirus (HPV) genital infection. Out of a cohort of 605 women included in a study of 
HPV infection prevalence, 142 HPV positive women (aged 18-57) were retested after a 12-month 
interval. None of the patients underwent surgical treatment during that period. Selected patients were 
asked for a second smear for cytologic analysis and HPV genotyping. A questionnaire that included 
information regarding reproductive health, sexual activity and smoking status was filled-in. After 12 
months, 46 of 142 (32.39%) women had persistent HPV infection, with genotypes 16 and 18 found 
in 27 cases. On the other hand, 17 of 142 (11.97%) women had acquired new infections replacing the 
baseline genotypes. In our study, smoking (OR=2.320, p=0.0330) and sexual behavior (OR=5.333, 
p=0.0180 for more than three sexual partners; OR=2.427, p=0.0238 for cases where the partner was 
involved in another sexual relationship) were associated with viral persistence, while long-term con-
traception did not yield statistically significant results.
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Introduction
Human papillomaviruses (HPV) have epithelial 
tropism and are found at certain anatomic sites where 
they can cause specific lesions or cancer. HPV infec-
tion is frequently associated with cervical lesions and 
oral diseases1. Genital infection is one of the most 
common sexually transmitted diseases in both men 
and women as almost 50% of sexually active persons 
tested positive at some point in their lives2,3. The risk of 
acquisition is higher in young subjects, in persons hav-
ing sex with multiple partners or in case of unprotect-
ed intercourse4,5. Ho et al.6 report that more than half 
of new genital infections resolve within one year, while 
90% resolve within two years. In most cases, HPV in-
fections have a transient character, particularly in 
young women, but in a small percentage of cases it 
persists7. Persistence of infection with high-risk geno-
types (hrHPV) is a necessary (but not sufficient) pre-
condition for development of cervical cancer. In Ro-
mania, the incidence of cervical cancer is among high-
est in Europe8 and this type of cancer remains one of 
the main causes of mortality in women9.
Persistent hrHPVs along with other cofactors pro-
moting cell transformation may lead to a severe dis-
ease10. Among the risk factors that might determine 
persistent infection are hrHPV genotypes, viral load 
and lifestyle factors11. The ability of some individuals 
to clear these viral infections appears to correlate with 
host genetics, HPV genotypes, host immune response 
characteristics12, and other cofactors. Epidemiological 
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data have confirmed that these cofactors include long 
term oral contraceptive use, smoking (through the mu-
tagenic activity of cigarette components), alcohol con-
sumption, parity and presence of other sexually trans-
mitted diseases such as infections with herpes simplex 
virus type 2, cytomegalovirus, and Chlamydia tracho-
matis13,14. Development of cervical cancer takes years/
decades after initial HPV infection and involves grad-
ual cytologic stages (low- and high-grade intraepithe-
lial lesions) characterized by the presence of hrHPV 
genotypes. These genotypes were identified in approxi-
mately 90% of cervical neoplasia cases, confirming the 
etiologic role of this viral infection in cancer develop-
ment15,16. Cytologic screening may reduce the inci-
dence of cervical cancer but it has a limited sensitivity 
and the quality of results depends on trained cytopa-
thologists. On the other hand, hrHPV DNA testing is 
considered a more sensitive technique to identify 
women at risk of developing cervical lesions17. Many 
national cervical screening programs recommend 
HPV testing and genotyping in women aged >30 (as 
spontaneous clearance is believed to occur below this 
age) in order to detect women at risk to develop severe 
lesions18-20.
The aim of this study was to identify factors associ-
ated with persistent HPV infection in a small cohort 
of women with cervical HPV infection.
Subjects and Methods
Out of a cohort of 605 women included in a study 
of the prevalence of HPV infection, 142 HPV positive 
women (aged 18-57) were randomly selected for cyto-
logic and viral retesting after 12 months. Cervical 
specimens were collected by a gynecologist and con-
ventional cytologic samples were interpreted by trained 
cytopathologists and reported using the 2001 Bethes-
da System. For viral tests, exfoliated cervical cells were 
harvested in Collection and Transport System medi-
um (Copan, Brescia, Italy). None of the patients re-
ported use of vaginal medication in the previous 2 days 
and no gynecologic investigation for the last year be-
fore enrolment. The gynecologist also asked the par-
ticipants to fill-in a questionnaire in order to collect 
information on reproductive health, sexual activity and 
smoking status. All the samples were obtained upon 
patient agreement and the study protocol was ap-
proved by the institutional Ethics Committee.
DNA isolation
DNA isolation from cervical smears was performed 
with the High Pure PCR Template Preparation Kit 
(Roche Molecular Biochemicals, Mannheim, Germa-
ny), according to the manufacturer’s recommenda-
tions. One milliliter of cellular suspension was centri-
fuged for 10 minutes at 12000 rpm and the pellet was 
disrupted with a lysis buffer and K proteinase (10 min-
utes, 70 °C). The mixture obtained was then treated 
with isopropanol; DNA was obtained by passing the 
mixture through purifying columns followed by 8000g 
centrifugation for several times. Isolated DNA sam-
ples were subsequently stored at -20°C. The concentra-
tion and purity of each one were evaluated by a Nano-
Drop spectrophotometer (NanoDropTechnologies, 
Montchanin, Delaware, USA).
HPV genotyping
HPV genotyping was performed using the Linear 
Array HPV Genotyping Test (Roche Molecular Bio-
chemicals, Mannheim, Germany), according to the 
manufacturer’s instructions. This kit is registered for 
use in the European Union and allows detection of 37 
HPV genotypes, including the high-risk types 16, 18, 
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68 
(http://molecular.roche.com). The method is based on 
polymerase chain reaction (PCR) DNA amplification 
followed by hybridization. For PCR amplification, bi-
otinylated primers that amplify near 450 base pairs 
from L1 viral gene were used. The mastermix con-
tained 10 µL DNA, 10 mM Tris HCl (pH 9.0), 50 
mM KCl, 2 mM MgCl2, 200 mM of each dNTP, 1.5U 
Ampli Taq Gold and 15 pM of each primer in a final 
volume of 50 µL. PCR thermal conditions were as fol-
lows: 95 °C for 9 minutes, 40 cycles of 30 seconds at 95 
°C denaturation, annealing 45 seconds at 52 °C and 
extension 45 seconds at 72 °C, followed by final exten-
sion of 5 minutes at 72 °C. The resulting PCR prod-
ucts were hybridized to molecular probes immobilized 
on a strip. An additional primer pair targets the human 
β-globin gene to provide control for cell adequacy, ex-
traction and amplification.
Statistical analysis
The GraphPad Prism ver. 5.0 software was used on 
statistical analysis. Fisher exact test was performed as a 
statistical tool; relative risk (RR) and odds ratio (OR) 
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were computed with 95% confidence interval (95% 
CI). The level of statistical significance was set at 
p<0.05.
Results and Discussion
Viral testing of selected patients at baseline re-
vealed the presence of hrHPV genotypes as single 
 infection in 53 (37.32%) and as co-infection in 50 
(35.21%) cases. Among high-risk genotypes, HPV 16 
was prevalent, being identified (both in single and co-
infections) in 37 (26.06%) cases, followed by HPV 18 
found in 25 (17.61%) and HPV 31 in 16 (11.27%) 
patients.
Upon dividing study patients into three age sub-
groups (<29, 30-39 and >40 years), the highest per-
centage of hrHPV single infections and hrHPV co-
infections was recorded in women of the 30-39 and 
<30 age groups, respectively (Table 1).
At baseline, 74 patients were negative for intraepi-
thelial lesion or malignancy (NILM), 17 were classi-
fied as atypical squamous cells of undetermined 
significance (ASCUS) and 51 as low-grade squamous 
intraepithelial lesion (LSIL).
After 12 months, all 142 women included in the 
study were retested both for HPV DNA and genotype, 
and for cytologic status. Persistent infection is con-
firmed by the presence of the same HPV genotype on 
two or more consecutive tests21. Follow-up genotyping 
for hrHPVs could be more accurate in predicting the 
risk of viral infection. In patients with persistent infec-
tion, Schiffman et al. noted the risk of acquiring a ma-
lignant phenotype to be very high for 5% of HPV in-
fections that persist for several years22.
In our study group, at follow-up we found 63 of 
142 women (44.37%) to be still HPV positive, while 
79 (55.63%) tested negative. Among positive samples 
at follow-up, the same genotypes were detected in 46 
(32.39%) cases, whereas the rest of 17 positive cases 
infected with different HPV genotypes were not in-
cluded in statistical analysis of the factors associated 
with persistence. According to HPV status at follow-
up, patients were divided into three groups, as follows: 
group A, patients having cleared the infection (79 
cases); group B, patients testing positive for the same 
genotype(s) – persistent infection (46 cases); and 
group C, patients testing positive for genotypes other 
than baseline (17 cases) (Table 2).
At follow-up, HPV 16 was found in 16, HPV 18 in 
11 and HPV 31 in 8 cases. The increased persistence of 
HPV 16 may have also been due to the viral variants 
found in our country23. It should be noted that geno-
types 18 and 31 were also found to have a rather high 
prevalence both at baseline and at follow-up. These 
data are consistent with other studies of the prevalence 
of HPV in Romania8,9. Overall, 60 cases of hrHPV 
were recorded both in persistent single and co-infec-
tions.
During the study period, cytologic profile im-
proved in group A, worsened in group B and remained 
almost unchanged in group C. These data are present-
ed in Table 3.
At baseline, cytologic diagnosis was NILM in 74 
patients and ASCUS or worse in 68 patients. At fol-
low up, we found 70 patients with NILM and 72 pa-
tients with ASCUS or worse, but the distribution of 
NILM/ASCUS or worse, as well as the evolution of 
cytologic status was very different between the patients 
having cleared the infection and those with persistent 
infection. To be more specific, in group A the number 
of patients with cytologic diagnosis of NILM in-
creased from 47 at baseline to 51 at follow up, whereas 
the number of those having ASCUS or LSIL cytology 
decreased from 32 to 28; in group B, only 10 out of 19 
cases retested NILM cytology at follow up, whereas 
the number of patients with ASCUS and LSIL in-
creased from 27 to 36 (Fig. 1). These data show that 
in our patients, clearance of infection was associated 
with improvement, and persistence of infection with 
worsening of the cytologic status.
To correlate viral persistence with cofactors (smok-
ing, marital status, number of partners, pregnancies or 
long-term oral contraceptive use), Fisher exact test 
with 95% CI was performed; HPV negative patients at 
follow up (n=79) were considered as a reference versus 
those presenting persistent infection (n=46). Since 
only 14% of the study subjects reported condom use, 
this parameter was not included in the statistics. The 
contribution of each genotype to viral persistence was 
difficult to estimate because of the small number of 
cases (no statistical significance was obtained). Statis-
tical analysis results are presented in Table 4.
Smoking, increased number of sexual partners or 
partners having sex with other partners better corre-
lated with infection persistence. The most statistically 
significant results were obtained for patients who de-
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Table 1. Distribution of viral infection types according to patient age
Age (yrs) Cases, n hrHPV single infection hrHPV co-infection lrHPV infection
<30 53 16 (11.27%) 19 (13.38%) 18 (12.67%)
30-39 59 25 (17.61%) 15 (10.56%) 19 (13.38%)
>40 30 12 (8.45%) 16 (11.27%) 2 (1.41%)
hrHPV = high-risk human papillomavirus; lrHPV = low-risk human papillomavirus













(other genotype),  
n
High risk
16 37 16 16 5
18 25 10 11 4
31 16 6 8 2
33 6 2 3 1
35 1 1 0 0
39 2 0 1 1
45 5 3 1 1
51 10 6 3 1
52 2 1 1 0
53 10 8 2 0
56 1 1 0 0
58 7 2 3 2
59 3 1 2 0
66 15 6 7 2
68 13 8 2 3
Low risk
6 9 5 3 1
11 8 7 0 1
40 3 3 0 0
54 6 4 1 1
61 3 2 1 0
62 5 3 2 0
70 4 4 0 0
71 1 0 1 0
HPV = human papillomavirus; N = number of patients; n = number of specific HPV genotype identified in 
patient subgroups
Table 3. Cytologic profile of study patients at baseline and follow up
Case group Baseline Follow up
(n) NILM ASCUS LSIL NILM ASCUS LSIL
Group A (79) 47 8 24 51 16 12
Group B (46) 19 6 21 10 18 18
Group C (17) 8 3 6 9 2 6
Total 74 17 51 70 36 36
NILM = negative for intraepithelial lesion or malignancy; LSIL = low-grade squamous intraepithelial lesion; 
ASCUS = atypical squamous cells of undetermined significance
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clared more than three sexual partners (p=0.0180, 
OR=5.333) and for cases where the partner was in-
volved in another sexual relationship (p=0.0238, 
OR=2.427). Good correlations recorded for smoking 
(p=0.0330, OR=2.320) may be explained by the effect 
of this habit on the immune system24. It is also impor-
tant to stress that in our country, the incidence of 
smoking is about 23% for female population, accord-
ing to the latest estimates9. The results of our study 
indicated that in our case group, smoking and sexual 
behavior were associated with viral persistence. Long-
term oral contraception did not yield a statistically sig-
nificant result (p>0.05), while having more than two 
pregnancies was not significantly correlated with ei-
ther persistence or clearance (p=0.2647).
Social background could influence the acquisition 
of HPV25, but in our study that included a small num-
ber of cases, no statistically significant correlations 
were observed between HPV persistence and level of 
education. Most of the participants were from urban 
areas (128 of 142 of cases), 85/142 reported high edu-
cation, 26/142 had completed high school, and only a 
small number (14/142) had completed elementary 
school.
Persistent HPV infection is a necessary but not 
sufficient cause for cervical cancer development2,26, and 
fortunately, most of these infections have a transient 
nature16. As observed in large screening studies, long-
term hrHPV infections that pass through different 
pre-malignant stages are more likely to lead to can-
cer21.
Detecting HPV and discriminating high- and low-
risk genotypes may not be enough, on the one hand 
because of the great number of transient infections, 
Fig. 1. Distribution of patients with NILM and ASCUS 
or worse cytology in clearance and persistence groups.
LSIL = low-grade squamous intraepithelial lesion; ASCUS = atyp-
ical squamous cells of undetermined significance; NILM = negative 
for intraepithelial lesion or malignancy
Table 4. Correlation between human papillomavirus (HPV) persistence and cofactors
Clearance Persistence RR 95% CI OR 95% CI p
Smoking No 58 25 1.351 1.004 to 1.817 2.320 1.079 to 4.988 0.0330*Yes 21 21
Age at first sexual 
intercourse 
>20 23 19 0.7049 0.4331 to 1.147 0.5836 0.2725 to 1.250 0.1752≤20 56 27
Number of partners <4 76 38 1.165 1.013 to 1.339 5.333 1.337 to 21.27 0.0180*≥4 3 8
Partners having 
other partners
No 53 21 1.470 1.034 to 2.088 2.427 1.150 to 5.119 0.0238*Yes 26 25
Married Yes 62 29 1.245 0.9699 to 1.598 2.138 0.9566 to 4.778 0.0945No 17 17
Pregnancies <3 41 29 0.8232 0.6058 to 1.119 0.6325 0.6144 to 2.430 0.2647≥3 38 17
Oral contraceptive 
use
Yes 34 12 1.650 0.9530 to 2.856 2.141 0.9669 to 4.740 0.0830No 45 34
*Statistically significant at p<0.05; RR = relative risk; 95% CI = 95% confidence interval; OR = odds ratio
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and on the other hand because persistent hrHPV in-
fection correlates with malignancy. Persistent infec-
tions can only be detected by genotyping, when the 
same genotype is found at retesting. Taking these facts 
in consideration, genotyping-based screening com-
bined with Papanicolaou test has better chances to 
find patients with persistent infections associated with 
modified cytology, resulting in better clinical manage-
ment14-17. Still, due to a large number of transient in-
fections found in women aged <30, viral screening is 
efficient for patients over this age, as demonstrated in 
our study.
Due to the small number of cases, we were unable 
to evaluate the contribution of different genotypes to 
persistence of infection, but HPV 16 was found most 
frequently on retesting in our study group (16 out of 
46 cases of persistent infection).
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Sažetak
ČIMBENICI UDRUŽENI S USTRAJNOM GENITALNOM INFEKCIJOM  
HUMANIM PAPILOMAVIRUSOM U MANJOJ SKUPINI RUMUNJSKIH ŽENA
I. Huică, I.V. Iancu, A. Botezatu, A. Pleşa, D. Socolov, S. Teleman i G. Anton
Cilj ovoga istraživanja bio je procijeniti ulogu čimbenika ponašanja na ustrajnost genitalne infekcije humanim papiloma-
virusom (HPV). Od 605 žena uključenih u ispitivanje učestalosti infekcije HPV-om 142 žene pozitivne na HPV (u dobi od 
18 do 57 godina) ponovno su testirane nakon 12 mjeseci. Tijekom tog razdoblja nijedna od tih bolesnica nije bila podvrgnu-
ta kirurškom liječenju. Od odabranih bolesnica zatražen je drugi obrisak za citološku analizu i genotipiziranje HPV-a. Ispu-
njen je upitnik s podacima o reprodukcijskom zdravlju, seksualnim aktivnostima i pušenju. Nakon 12 mjeseci 46/142 
(32,39%) žena imalo je ustrajnu infekciju HPV-om; u 27 slučajeva utvrđeni su genotipovi 16 i 18. S druge strane, 17/142 
(11,97%) žena imalo je novo stečene infekcije koje su zamijenile prvobitne genotipove. U našem istraživanju je pušenje 
(OR=2,320, p=0,0330) i spolno ponašanje (OR=5,333, p=0,0180 za više od tri seksualna partnera; OR=2,427, p=0,0238 u 
slučajevima kad je partner imao i drugi seksualni odnos) bilo udruženo s ustrajnošću virusa, dok dugotrajna kontracepcija nije 
pokazala statistički značajne rezultate.
Ključne riječi: Papilomavirus, infekcije; Seksualno ponašanje; Ankete i upitnici; Rumunjska
